Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination

Faculty Medicine Year: 2020
Type of Publication: ZU Hosted Pages:
Authors:
Journal: J Gastrointest Cancer springer Volume:
Keywords : Prognostic Significance , VEGF , HIF-1 , , Hepatocellular Carcinoma    
Abstract:
Background: Hepatocellular carcinoma (HCC) is a major health problem. HCC burden has been increasing in Egypt in the past 10 years. Most HCC cases are diagnosed at an advanced stage with limited treatment options. Sorafenib is the standard therapy for advanced HCC, but the effectiveness is not satisfied. Metformin may decrease the risk of HCC development in diabetic patients, reduces tumor invasion, and augments sensitivity to sorafenib; however, safety and efficacy of combined treatment are still unclear. As HCC is characterized by high vascularity, and vascular endothelial growth factor (VEGF) plays an important role in vascularization, many studies questioned if VEGF and HIF-1 α could offer information about HCC response to sorafenib. We conducted this study to assess the benefits from adding metformin to HCC treatment, and appraise the role of VEGF and HIF-1 α in HCC prognosis. Method: This was a prospective, randomized study in which 80 advanced measurable patients consecutively treated with sorafenib plus metformin (arm A) or sorafenib alone (arm B), prognostic value of plasma, and tissue levels of VEGF and HIF-1 α were evaluated. Results: We enrolled 61 men and 19 women with a median age of 60 years (range 49-68 years). Fifty-seven patients had Child-Pugh A while 23 had early B, the most common etiology of liver disease was hepatitis C (86%). Sixty percent of patients were diabetic. No significant difference was detected between arm A and arm B regarding response to treatment (p = 0.5), time to disease progression (p = 0.3), or overall survival (p = 0.6). Low VEGF and HIF-1 α plasma levels were significantly associated with better treatment response (p < 0.001 for both), and higher OS (p < 0.001). Patients with high expressions of VEGF and HIF in HCC tissue had significantly poor treatment outcome (p < 0.001, p = 0.03, respectively), and poor OS (p < 0.001, p < 0.001, respectively). Conclusions: No superior efficacy of adding metformin to sorafenib in HCC treatment. VEGF and HIF-1 α had promising prognostic value in HCC.
   
     
 
       

Author Related Publications

  • Rasha Mohamed Mostafa Hagag, "Impact of Prognostic Nutritional Index and Systemic Immune-Inflammation Index on the Clinical Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib", Zagazig University Medical Journal, 2022 More
  • Rasha Mohamed Mostafa Hagag, "Diagnosis of Sepsis among Adult Patients with AML Using Scd14", Ain Shams University, Faculty of Medicine, Pan Arab League of Continuous Medical Education, 2021 More
  • Rasha Mohamed Mostafa Hagag, "Prognostic Impact of microRNAs (miR-155, miR-10a, let-7a) on the Outcome of Adult Patients with Acute Myeloid Leukemia.", Zagazig University, Faculty of Medicine, 2021 More
  • Rasha Mohamed Mostafa Hagag, "نمط الوفيات الناجمة عن السرطان في مستشفى رعاية ثالثية سعودي", Volume 30, Issue 1, February, 2012, Pages 21-24, 2012 More
  • Rasha Mohamed Mostafa Hagag, "نمط الصفات الاكلينيكيه و الباثولوجيه و معدل بقاء مرضى سرطان القولون و المستقيم صغار السن: تجربه من غرب المملكه العربيه السعوديه", Asian Pacific Journal of Cancer Prevention Volume 1, Issue 13, February, Pages 5239-5243, 2014, 2013 More

Department Related Publications

  • Foad Mohamed Mohamed Abotaleb, "الاحتفاظ بالمثانة البولية فى سرطان الخلايا الانتقالية التوسعى عن طريق الاستئصال الجزئى عبر قناة مجرى البول والعلاج الكيميائى سى . أم . ف", لايوجد, 1900 More
  • Foad Mohamed Mohamed Abotaleb, "المضاعفات الكبدية التى تحدث بعد عملية زرع النخاع العظمى الذاتى لمرضى سرطان الغدد الليمفاوية الذين يحملون الاجسام المضادة لفيروس الالتهاب الكبدى الوبائى من النوع سى", لايوجد, 1900 More
  • Shereen Mostafa Saleh Elshorbagy, "- Detection of Paroxysmal Hemogloinuria Clones In patients With Pancytopenia", . IJAR 3,12,866-875; 2015, 2015 More
  • Shereen Mostafa Saleh Elshorbagy, "- CD19 and CD56 Antigens Expression in Acute Myeloid Leukemia Identifies Patients with Prognosis in Egypt Adverse", . IJSR 5; 2016, 2016 More
  • Ahmed Abdelrehem Ahmed Abdulrihem, "Significance of PAX (CDX2) gene expression in adult acute Myeloid leukemia", http://www.journalijar.com/, 2015 More
Tweet